AFP-L3: a new generation of tumor marker for hepatocellular carcinoma

Li, Dave; Mallory, Tonya; Satomura, Shinji

doi:10.1016/s0009-8981(01)00644-1

Cited by 313 publications

(247 citation statements)

References 22 publications

Supporting

Mentioning

237

Contrasting

Unclassified

Order By: Relevance

“…Therefore, AFP-L3 has been recognized as a specific marker for HCC. Furthermore, analysis using this marker could be useful for monitoring treatment responses and disease recurrence and could also be a tool for recognition of HCC earlier than that possible by using imaging modalities (34,(37)(38)(39)(40)(41)(42). In recent years, in addition to AFP, new biomarkers possessing fucosides have been discovered.…”

Section: Discussionmentioning

confidence: 99%

A Novel Core Fucose-specific Lectin from the Mushroom Pholiota squarrosa

Kobayashi

Tateno

Dohra

et al. 2012

Journal of Biological Chemistry

110

View full text Add to dashboard Cite

Background: Fuc-␣1-6 oligosaccharide has a variety of biological functions. Results: Purification of a novel Fuc␣ 1-6-specific lectin from the mushroom Pholiota squarrosa. Conclusion: The lectin binds only to core ␣1-6-fucosylated N-glycans and not to the other types of fucosylated oligosaccharides. Significance: The lectin will be a promising tool for analyzing the biological functions of ␣1-6 fucosylation.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Core Fucose-specific Lectin from the Mushroom Pholiota squarrosa

Kobayashi

Tateno

Dohra

et al. 2012

Journal of Biological Chemistry

110

View full text Add to dashboard Cite

show abstract

“…The best coexpression pattern was between CD133 and AFP. However, AFP is a well-characterized marker that is used to detect all HCCs [39], and CD133 expression appears to be non-specific with no significant difference in expression between human HCC tumor tissues and adjacent noncancerous tissues. Furthermore, AFP appears to be markedly up-regulated in Ep-CAM-enriched HuH7 cells, but not in PLC/PRF/5 cells, suggesting a possible cell-specific phenotype.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

Wilson

Duan

et al. 2013

Stem Cells and Development

View full text Add to dashboard Cite

Recent evidence suggests that a subset of hepatocellular carcinomas (HCCs) are derived from liver cancer stem cells (LCSCs). In order to isolate and characterize LCSCs, reliable markers that are specific to these cells are required. We evaluated the efficacy of a range of cancer stem cell (CSC) markers in isolating and characterizing LCSCs. We show that the most widely used CSC markers are not specific to LCSCs. By western analysis, protein expression of the common markers showed no significant difference between HCC tumor tissues and adjacent non-cancerous liver. Further, isolation of LCSCs from common HCC cell lines using FACScan and microbeads showed no consistent marker expression pattern. We also show that LCSCs have unique subtypes. Immunohistochemistry of HCC tissues showed that different HCCs express unique combinations of LCSC markers. Quantitative real-time polymerase chain reaction analysis showed that LCSCs isolated using different markers in the same HCC phenotype had different expression profiles. Likewise, LCSCs isolated from different HCC phenotypes with the same marker also had unique expression profiles and displayed varying resistance profiles to Sorafenib. Thus, using a range of commonly used CSC markers in HCCs and cell lines, we demonstrate that currently available markers are not specific for LCSCs. LCSCs have unique subtypes that express distinctive combinations of LCSC markers and altered drug resistance profiles, making their identification problematic.

show abstract

“…Most clinical tumor markers are glycoproteins; however, detection of specific cancer-associated alterations in glycan structures, such as alpha-fetoprotein-(AFP)L3 (9,10), may improve their specificity; furthermore, novel biomarkers are currently being discovered (11).…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of serum tumor abnormal protein in gastric cancer patients

Feng

Zhu

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Aberrant glycosylation of protein occurs in nearly all types of cancers and has been confirmed to be associated with tumor progression, metastasis and the survival rate of patients. The present study aimed to explore the prognostic value of tumor abnormal protein (TAP) in gastric cancer patients. TAP was detected in the blood of 42 gastric cancer patients and 56 healthy volunteers by using the TAP testing kit. Univariate and multivariate Cox regression analysis were performed to evaluate the prognostic value of TAP. In total, 64.3% of gastric cancer patients were positive for TAP, and TAP was significantly correlated with poor prognosis [progression-free survival (PFS), 4.2 vs. 12.6 months; P= 0.043]. TAP [hazard ratio (HR), 64.487; P<0.01), differentiation (HR, 17.279; P<0.01) and TNM stage (HR, 45.480; P<0.01) were found to be independent predictive factors for PFS. Furthermore, Kaplan-Meier curves indicated that TAP is associated with a reduced PFS in gastric cancer patients. The results of the present study therefore indicated that the TAP test has significant prognostic value for gastric cancer patients.

show abstract

AFP-L3: a new generation of tumor marker for hepatocellular carcinoma

Cited by 313 publications

References 22 publications

A Novel Core Fucose-specific Lectin from the Mushroom Pholiota squarrosa

A Novel Core Fucose-specific Lectin from the Mushroom Pholiota squarrosa

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

Prognostic value of serum tumor abnormal protein in gastric cancer patients

Contact Info

Product

Resources

About